Doxazosin mesylate NDC 62135-052

NDC codes

FDA NDC Directory

Product NDC (as listed)62135-052Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62135-0052Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62135-052-90	62135005290	90 TABLET in 1 BOTTLE (62135-052-90)Marketed from Jun 6, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Doxazosin mesylate
Generic name (nonproprietary): doxazosin mesylate
Active ingredients: Doxazosin mesylate — 2 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Chartwell RX, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075646
Marketing start: Oct 18, 2000
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic alpha-Antagonists (Mechanism)
Identifiers: Product ID 62135-052_fdb507a5-0211-0689-e053-6394a90a860aSPL ID fdb507a5-0211-0689-e053-6394a90a860aSPL set ID a7f589b0-eebb-48cb-912f-a4bd956e4dcbRxCUI 197625, 197626, 197627, 197628UNII 86P6PQK0MUUPC 0362135052904, 0362135051907, 0362135053901, 0362135054908
Pharmacologic class: alpha-Adrenergic Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462135005290 followed by a unit qualifier and the quantity

Package 62135-0052-90. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 9, 2023.

Indications (excerpt from the label)

Doxazosin mesylate tablets are an alpha 1 adrenergic antagonist indicated for: ( 1 ) Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 075646

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 075646
Product	Strength	Form · route	Labeler	Product NDC
Doxazosin mesylate	Doxazosin mesylate 4 mg/1	TabletOral	Chartwell RX, LLC	62135-053
Doxazosin mesylate	Doxazosin mesylate 1 mg/1	TabletOral	Chartwell RX, LLC	62135-051
Doxazosin mesylate	Doxazosin mesylate 8 mg/1	TabletOral	Chartwell RX, LLC	62135-054